Abivax is involved in the development of obefazimod, a molecule that works by enhancing the expression of miR-124 to regulate the immune response and treat chronic inflammatory diseases. The molecule is currently in clinical trials for conditions such as ulcerative colitis and rheumatoid arthritis.

Abivax

Abivax | 11,034 followers on LinkedIn. Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease.

Biopharma C-suite Executive & Board Director┃ International P&L Management┃ Global Portfolio & Product Strategy, Commercialisation and Life Cycle…

Camilla Soenderby

Fabio Cataldi

Chief Business Officer at ABIVAX

Pierre Courteille

Marc de Garidel

Join Abivax at our Symposium “Oral Advanced Therapies in UC: Are more Options Needed?” with Professor Dubinsky & Professor Vermeire on Sunday, October 13th from 10-11am CEST at #UEGWeek 2024.

Abivax is excited to be part of #UEGWeek , October 12-15, in Vienna, Austria. We’re connecting with fellow #IBD researchers all week. Don’t forget to drop by booth #11 to learn more about Abivax!

At the core of the science behind Abivax is miR-124, a #microRNA that is well characterized in the scientific literature. miR-124 interacts with specific messenger RNA targets, decreasing their translation into their respective proteins. For more information about our science, visit https://lnkd.in/eKZnghcg .

What an incredible week at #DDW2024 ! Thank you to all who stopped by our booth—we loved discussing our work and research in #IBD .

Read what Sheldon Sloan, MD, M Bioethics, Abivax Chief Medical Officer had to say about the role of small molecule drugs in #autoimmune and chronic conditions like #ulcerativecolitis with European Pharmaceutical Review :

#IBD impacts quality of life for millions worldwide. We are proud to be developing a potential new treatment option for people with chronic inflammatory diseases, like #InflammatoryBowelDisease . Learn more about our commitment to people with IBD: https://lnkd.in/ev-3RDxR #WorldIBDDay

Tomorrow is #WorldIBDDay . #IBD is a term used to describe conditions characterized by chronic inflammation of the #GI tract, such as ulcerative colitis and Crohn’s disease. Abivax strives to develop therapies to effectively treat inflammatory bowel diseases and improve the lives of people with IBD.

We are looking forward to attending Digestive Disease Week® (DDW) in Washington, DC. Visit booth 529 to learn more about Abivax and connect with fellow #IBD researchers. #DDW2024

This #InternationalDayOfFamilies we are highlighting the unique role families play in supporting a loved one or close friend with #IBD . Your support can make a monumental difference in the health and happiness of people living with IBD. Today, we would also like to honor the importance of your dedication and resilience.

We’re excited to share the launch of our new corporate website. Explore its new look and the latest updates at https://www.abivax.com .

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

COM:ABIVAX

Abivax

Last Close

9.67

12/11 16:35

Market Cap

790.24M

Beta: -

Volume Today

24.70K

Avg: -

Analysis Not Available